Neuspera Reports Positive 12-Month Results for Urinary Incontinence Therapy

Neuspera Medical has announced encouraging 12-month results from its pivotal trial evaluating the Neuspera SNM integrated sacral neuromodulation (iSNM) system for patients with Urinary Urge Incontinence (UUI). The findings were presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting.

Data from 128 implanted patients showed strong clinical outcomes. Among test-phase responders, 94% experienced at least a 50% reduction in UUI episodes. Additionally, 81% were classified as super-responders, achieving a reduction of 75% or more, while 43% became completely dry.

The Neuspera system uses an ultra-miniaturised implant powered by an external transmitter, designed to avoid issues associated with traditional devices such as infections and battery replacement surgeries.

Safety results were favourable, with no serious device-related adverse events or infections reported during the 12-month period. The U.S. Food and Drug Administration approved the system for UUI treatment in June 2025.

08-03-2026